SAN FRANCISCO and HONG KONG, Oct. 12 /PRNewswire/ — Burrill
& Company, a leading life sciences venture capital/private
equity firm and Infinity Group, an RMB fund pioneer and the leading
cross border China dollar and RMB private equity fund announced
today that they have established a strategic partnership . The
mandate of the joint venture will be to pursue life science
investment opportunities in China; Burrill and Infinity will
co-invest as equal partners in US dollar and RMB investments.
Infinity’s China expertise and network, currently spanning ten
well developed cities in China, combined with Burrill &
Company’s US and global experience and networks create an
unparalleled, China-focused, life sciences partnership. Under
the terms of the partnership agreement, Burrill will establish
headquarters for its China operations in Hong Kong where Infinity
already has an established presence; it will also utilize all 10 of
Infinity’s offices in Greater China as well as its international
offices located in the United States, Europe and Asia. Infinity
will strengthen its presence in the United States through this
cooperation, which is part of Infinity’s strategy to enhance its
position as a global life science fund bringing innovative
technologies from Israel, the US and Europe to China.
“We are very excited about this joint venture as this
partnership will be able to build upon our complementary focus
areas internationally,” said G. Steven Burrill, CEO, Burrill &
Company, a San Francisco based global leader in life sciences with
activities in private equity, venture capital, merchant banking and
media. “We will be able to bring our venture capital/private equity
operations with our focus on innovation to delivery in healthcare,
as well as activities in life sciences publications and events to
Infinity’s extensive operations and networks in China.”
“We have developed a unique and unparalleled network of
partnerships
‘/>”/>
